Neurology Clinical Trials Global Market Report 2025
상품코드:1810974
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
신경학 임상시험 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 6.8%로 75억 4,000만 달러로 성장합니다. 예측 기간 중 성장의 배경에는 정밀의료의 채택 증가, 바이오마커 기반 연구에 대한 관심 증가, 시험 설계에서 인공지능의 적용 증가, 신경계 약물 파이프라인 증가, 신경계 연구에 대한 정부 지원 및 자금 지원 강화 등이 있습니다. 이 기간 중 예상되는 주요 동향으로는 신경 영상 기술의 발전, 환자 계층화를 위한 고급 데이터 분석의 활용, 적응형 시험 설계의 출현, 신경 모니터링용 웨어러블 기기의 혁신, 분산형 임상시험 모델 개발 등이 있습니다.
신경질환의 유병률 증가는 향후 수년간 신경학 임상시험 시장의 성장을 가속할 것으로 예측됩니다. 신경질환이란 뇌, 척수, 신경에 영향을 미쳐 신경계의 정상적인 기능을 저해하는 질환을 말합니다. 이러한 증가는 노인들이 알츠하이머병, 파킨슨병과 같은 노화 관련 질환에 걸리기 쉽기 때문에 인구 고령화와 밀접한 관련이 있습니다. 신경학 임상시험은 진단을 개선하고, 증상을 관리하고, 질병의 진행을 늦추고, 환자의 예후를 개선하기 위한 새로운 치료법, 약물, 중재법을 시험함으로써 이러한 질병에 대응하는 데 기여합니다. 예를 들어 2024년 9월 호주보건복지연구원(Australian Institute of Health and Welfare)은 2023년 41만 1,100명에서 2058년 84만 9,300명으로 2배 이상 증가할 것으로 예측했습니다. 두 배로 증가할 것으로 예측하고 있다고 보고했습니다. 그 무렵에는 남성 31만 5,500명, 여성 53만 3,800명이 치매를 앓고 있는 것으로 추정됩니다. 이러한 신경질환의 유병률 증가는 신경학 임상시험 시장 확대를 촉진하는 중요한 요인입니다.
신경학 임상시험 분야의 주요 기업은 모노클로널 항체 등 혁신적인 치료법 개발을 통해 치료적 접근을 진행하고 있습니다. 이러한 인공 분자는 특정 단백질이나 항원에 정확하게 결합하도록 설계되어 효능을 향상시키고 새로운 치료법 개발을 가속화할 수 있는 표적 치료 메커니즘을 제공합니다. 예를 들어 2024년 7월 미국 제약사 일라이 릴리(Eli Lilly and Company)는 초기 증상 알츠하이머병 치료제 키순라(donanemab-azbt)를 발표했습니다. 본 치료를 통해 인지기능 및 기능 저하를 지연시킬 수 있으며, 대상 환자가 독립성을 유지하고 일상생활을 영위할 수 있는 시간을 늘릴 수 있습니다. Kisunla는 뇌내 아밀로이드 플라크를 표적으로 감소시키는 약물로, 임상시험 결과, 진행이 덜 진행된 알츠하이머병 환자에서 위약 대비 질병 진행을 최대 35%까지 억제하는 것으로 나타났습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 신경학 임상시험 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 신경학 임상시험 시장 : 성장률 분석
세계의 신경학 임상시험 시장 실적 : 규모와 성장, 2019-2024
세계의 신경학 임상시험 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 신경학 임상시험 : TAM(Total Addressable Market)
제6장 시장 세분화
세계의 신경학 임상시험 시장 : 단계별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
단계 I
단계 II
단계 III
단계 IV
세계의 신경학 임상시험 시장 : 연구 디자인별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
개입적
관찰적
확장 액세스
세계의 신경학 임상시험 시장 : 적응증별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
간질
파킨슨병(PD)
헌팅턴병
뇌졸중
외상성 뇌손상(TBI)
근위축성측색경화증(ALS)
근육 재생
기타 적응증
세계의 신경학 임상시험 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
클리닉
조사기관
기타 최종사용자
세계의 신경학 임상시험 시장 : 서브 세분화, 단계 I, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
의약품 안전성 평가
약물 동태 평가
투여량 범위 탐색
인용성 연구
세계의 신경학 임상시험 시장 : 서브 세분화, 단계 II, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
유효성 평가
용량 반응 연구
치료 효과
바이오마커 식별
세계의 신경학 임상시험 시장 : 서브 세분화, 단계 III, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
대규모 유효성 연구
안전 감시
비교 효과
리스크 이익 분석
세계의 신경학 임상시험 시장 : 서브 세분화, 단계 IV, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
시판 후 조사
장기 안전성 팔로 업
RWE(Real World Evidence) 컬렉션
삶의 질 평가
제7장 지역별·국가별 분석
세계의 신경학 임상시험 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 신경학 임상시험 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
신경학 임상시험 시장 : 경쟁 구도
신경학 임상시험 시장 : 기업 개요
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
IQVIA Holdings Inc.
Biogen Inc.
ICON plc.
Syneos Health
Charles River Laboratories International Inc.
Parexel International Corporation
CMIC Holdings Co. Ltd.
Medpace Holdings Inc.
PSI CRO AG.
Supernus Pharmaceuticals Inc.
Worldwide Clinical Trials LLC.
Ergomed plc.
Biotrial S.A.S.
Clinilabs Drug Development Corporation
Lindus Health Ltd.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
신경학 임상시험 시장 2029 : 새로운 기회를 제공하는 국가
신경학 임상시험 시장 2029 : 새로운 기회를 제공하는 부문
신경학 임상시험 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁사 전략
제36장 부록
KSA
영문 목차
영문목차
Neurology clinical trials are research studies conducted to assess the safety, effectiveness, and outcomes of interventions like medications, therapies, or diagnostic methods for neurological conditions. These studies aim to improve treatments for disorders that impact the brain, spinal cord, and nervous system.
The primary stages of neurology clinical trials include Phase I, Phase II, Phase III, and Phase IV. Phase I is the initial stage, involving a small number of healthy individuals or patients, and focuses on evaluating a drug's safety, appropriate dosage range, and potential side effects. In the field of neurology, Phase I trials are particularly important for understanding how new treatments affect complex brain and nerve functions. The studies may follow different designs, such as interventional, observational, or expanded access. They address a variety of conditions, including epilepsy, Parkinson's disease (PD), Huntington's disease, stroke, traumatic brain injury (TBI), amyotrophic lateral sclerosis (ALS), muscle regeneration, and others. The primary users of these trials include hospitals, clinics, research centers, and related institutions.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The neurology clinical trials market research report is one of a series of new reports from The Business Research Company that provides neurology clinical trials market statistics, including the neurology clinical trials industry's global market size, regional shares, competitors with the neurology clinical trials market share, detailed neurology clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the neurology clinical trials market. This neurology clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The neurology clinical trials market size has grown strongly in recent years. It will grow from $5.42 billion in 2024 to $5.80 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historic period can be credited to the rising prevalence of neurological disorders, growing demand for advanced treatment options, an increase in the aging population, greater investment in research and development by pharmaceutical companies, and improved awareness and diagnosis rates of neurological conditions.
The neurology clinical trials market size is expected to see strong growth in the next few years. It will grow to $7.54 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The projected growth in the forecast period can be attributed to the increasing adoption of precision medicine, a stronger focus on biomarker-driven studies, the rising application of artificial intelligence in trial design, a growing pipeline of neurology drugs, and enhanced government support and funding for neurological research. Key trends expected during this period include advancements in neuroimaging technologies, the use of advanced data analytics for patient stratification, the emergence of adaptive trial designs, innovations in wearable devices for neurological monitoring, and the development of decentralized clinical trial models.
The rising prevalence of neurological disorders is anticipated to drive the growth of the neurology clinical trials market in the coming years. Neurological disorders are conditions that affect the brain, spinal cord, or nerves, disrupting the normal functioning of the nervous system. This rise is largely linked to the aging population, as older adults are more prone to age-related conditions such as Alzheimer's and Parkinson's disease. Neurology clinical trials contribute to addressing these disorders by testing new treatments, drugs, or interventions that aim to improve diagnosis, manage symptoms, slow disease progression, and enhance patient outcomes. For example, in September 2024, the Australian Institute of Health and Welfare reported that the number of Australians living with dementia is projected to more than double, from 411,100 in 2023 to 849,300 by 2058. By that time, it is estimated that 315,500 men and 533,800 women will be living with the condition. This growing prevalence of neurological disorders is a key factor fueling the expansion of the neurology clinical trials market.
Leading companies in the neurology clinical trials sector are advancing treatment approaches through the development of innovative therapies such as monoclonal antibodies. These engineered molecules are designed to bind precisely to specific proteins or antigens, offering targeted treatment mechanisms that improve efficacy and speed up the development of novel therapies. For instance, in July 2024, Eli Lilly and Company, a U.S.-based pharmaceutical firm, introduced Kisunla (donanemab-azbt) for the treatment of early symptomatic Alzheimer's disease. This treatment helps slow cognitive and functional decline, giving eligible patients more time to maintain independence and engage in daily activities. Kisunla targets and reduces amyloid plaques in the brain, with clinical trial results indicating up to a 35% reduction in disease progression compared to a placebo in patients with less advanced Alzheimer's.
In March 2025, CLARIO, a U.S.-based healthcare company, acquired NeuroRx to enhance its neuroscience capabilities and support the advancement of neurology drug development. This strategic acquisition aims to strengthen CLARIO's position in medical imaging and expand its expertise in neurological research. NeuroRx, based in Canada, is a clinical-stage pharmaceutical company involved in conducting neurology clinical trials.
Major players in the neurology clinical trials market are AbbVie Inc., Sanofi S.A., Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., IQVIA Holdings Inc., Biogen Inc., ICON plc., Syneos Health, Charles River Laboratories International Inc., Parexel International Corporation, CMIC Holdings Co. Ltd., Medpace Holdings Inc., PSI CRO AG., Supernus Pharmaceuticals Inc., Worldwide Clinical Trials LLC., Ergomed plc., Biotrial S.A.S., Clinilabs Drug Development Corporation, and Lindus Health Ltd.
North America was the largest region in the neurology clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neurology clinical trials report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the neurology clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The neurology clinical trials market consists of revenues earned by entities by providing services such as collecting and analyzing health data, monitoring patient safety, managing trial sites, regulatory consulting, and trial design and planning. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Neurology Clinical Trials Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on neurology clinical trials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for neurology clinical trials ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neurology clinical trials market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Phase: Phase I; Phase II; Phase III; Phase IV
2) By Study Design: Interventional; Observational; Expanded Access
3. Neurology Clinical Trials Market Trends And Strategies
4. Neurology Clinical Trials Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Neurology Clinical Trials Growth Analysis And Strategic Analysis Framework
5.1. Global Neurology Clinical Trials PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Neurology Clinical Trials Market Growth Rate Analysis
5.4. Global Neurology Clinical Trials Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Neurology Clinical Trials Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Neurology Clinical Trials Total Addressable Market (TAM)
6. Neurology Clinical Trials Market Segmentation
6.1. Global Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Phase I
Phase II
Phase III
Phase IV
6.2. Global Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Interventional
Observational
Expanded Access
6.3. Global Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle Regeneration
Other Indications
6.4. Global Neurology Clinical Trials Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Research Institutes
Other End- Users
6.5. Global Neurology Clinical Trials Market, Sub-Segmentation Of Phase I, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Drug Safety Evaluation
Pharmacokinetics Assessment
Dosage Range Finding
Tolerability Studies
6.6. Global Neurology Clinical Trials Market, Sub-Segmentation Of Phase II, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Efficacy Evaluation
Dose Response Studies
Therapeutic Effectiveness
Biomarker Identification
6.7. Global Neurology Clinical Trials Market, Sub-Segmentation Of Phase III, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Large Scale Efficacy Studies
Safety Monitoring
Comparative Effectiveness
Risk Benefit Analysis
6.8. Global Neurology Clinical Trials Market, Sub-Segmentation Of Phase IV, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Post Marketing Surveillance
Long Term Safety Follow Up
Real World Evidence Collection
Quality Of Life Assessment
7. Neurology Clinical Trials Market Regional And Country Analysis
7.1. Global Neurology Clinical Trials Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Neurology Clinical Trials Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
